US 2021/0261685 A1 · ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.

Claims36

Dependent claims

An isolated antibody that binds human Mer Tyrosine Kinase (MerTK), wherein the antibody reduces efferocytosis by a phagocytic cell.

An isolated antibody that binds to human MerTK, wherein the antibody comprises an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of:

(i) SEQ ID NOs:
75, 99, 125, 158, 187, and 207, respectively;
(ii) SEQ ID NOs:
76, 100, 126, 159, 187, and 208, respectively;
(iii) SEQ ID NOs:
77, 101, 127, 160, 188, and 209, respectively;
(iv) SEQ ID NOs:
75, 99, 128, 158, 187, and 210, respectively;
(v) SEQ ID NOs:
78, 102, 129, 161, 189, and 211, respectively;
(vi) SEQ ID NOs:
75, 103, 130, 158, 187, and 212, respectively;
(vii) SEQ ID NOs:
77, 101, 127, 162, 188, and 209, respectively;
(viii) SEQ ID NOs:
75, 99, 131, 163, 187, and 213, respectively;
(ix) SEQ ID NOs:
79, 104, 132, 164, 190, and 214, respectively;
(x) SEQ ID NOs:
80, 105, 133, 165, 191, and 215, respectively;
(xi) SEQ ID NOs:
81, 106, 134, 166, 192, and 216, respectively;
(xii) SEQ ID NOs:
82, 107, 135, 167, 193, and 217, respectively;
(xiii) SEQ ID NOs:
77, 108, 136, 167, 194, and 209, respectively;
(xiv) SEQ ID NOs:
75, 109, 137, 168, 187, and 218, respectively;
(xv) SEQ ID NOs:
83, 99, 138, 158, 187, and 210, respectively;
(xvi) SEQ ID NOs:
84, 99, 139, 169, 195, and 219, respectively;
(xvii) SEQ ID NOs:
85, 99, 140, 170, 196, and 220, respectively;
(xviii) SEQ ID NOs:
86, 99, 141, 171, 191, and 221, respectively;
(xix) SEQ ID NOs:87, 110, 142, 172, 197, and 222, respectively;
(xx) SEQ ID NOs:
88, 99, 143, 173, 191, and 223, respectively;
(xxi) SEQ ID NOs:
89, 111, 143, 173, 198, and 221, respectively;
(xxii) SEQ ID NOs:
90, 112, 144, 174, 199, and 224, respectively;
(xxiii) SEQ ID NOs:
91, 113, 145, 175, 200, and 225, respectively;
(xxiv) SEQ ID NOs:
90, 114, 146, 176, 201, and 226, respectively;
(xxv) SEQ ID NOs:
92, 115, 147, 177, 195, and 227, respectively;
(xxvi) SEQ ID NOs:
93, 116, 148, 178, 188, and 209, respectively;
(xxvii) SEQ ID NOs:
94, 117, 149, 179, 195, and 228, respectively;
(xxviii) SEQ ID NOs:
95, 118, 150, 180, 187, and 229, respectively;
(xxix) SEQ ID NOs:
95, 119, 151, 181, 187, and 208, respectively;
(xxx) SEQ ID NOs:
90, 120, 152, 182, 202, and 230, respectively;
(xxxi) SEQ ID NOs:
96, 118, 153, 183, 202, and 230, respectively;
(xxxii) SEQ ID NOs:
96, 121, 154, 181, 187, and 210, respectively;
(xxxiii) SEQ ID NOs:
90, 122, 155, 184, 203, and 231, respectively;
(xxxiv) SEQ ID NOs:
90, 122, 155, 184, 203, and 231, respectively;
(xxxv) SEQ ID NOs:97, 123, 156, 185, 204, and 232, respectively;
(xxxvi) SEQ ID NOs:
98, 124, 157, 186, 205, and 233, respectively;
(xxxvii) SEQ ID NOs:
83, 329, 334, 158, 187, and 210, respectively;
(xxxviii) SEQ ID NOs:
83, 330, 138, 158, 187, and 210, respectively;
(xxxix) SEQ ID NOs:
83, 329, 138, 340, 187, and 210, respectively;
(xl) SEQ ID NOs:
83, 329, 138, 341, 187, and 210, respectively;
(xli) SEQ ID NOs:
83, 329, 335, 341, 187, and 210, respectively;
(xlii) SEQ ID NOs:
83, 331, 138, 341, 187, and 210, respectively;
(xliii) SEQ ID NOs:
83, 329, 138, 342, 187, and 210, respectively;
(xliv) SEQ ID NOs:
83, 329, 336, 341, 187, and 210, respectively;
(xlv) SEQ ID NOs:
83, 329, 337, 343, 187, and 210, respectively;
(xlvi) SEQ ID NOs:
83, 332, 338, 341, 187, and 210, respectively;
(xlvii) SEQ ID NOs:
83, 333, 334, 158, 187, and 210, respectively;
(xlviii) SEQ ID NOs:
83, 332, 336, 341, 187, and 210, respectively;
(xlix) SEQ ID NOs:
83, 329, 339, 344, 187, and 210, respectively;
(l) SEQ ID NOs:
83, 329, 138, 158, 187, and 210, respectively;
(li) SEQ ID NOs:
84, 329, 139, 169, 195, and 219, respectively;
(lii) SEQ ID NOs:
84, 99, 139, 345, 195, and 219, respectively;
(liii) SEQ ID NOs:
346, 348, 355, 341, 187, and 360, respectively;
(liv) SEQ ID NOs:
95, 119, 355, 341, 187, and 361, respectively;
(lv) SEQ ID NOs:
95, 349, 356, 341, 187, and 362, respectively;
(lvi) SEQ ID NOs:
95, 119, 356, 341, 359, and 362, respectively;
(lvii) SEQ ID NOs:
346, 119, 356, 341, 359, and 362, respectively;
(lviii) SEQ ID NOs:
95, 350, 356, 341, 359, and 362, respectively;
(lix) SEQ ID NOs:
95, 351, 356, 341, 359, and 362, respectively;
(lx) SEQ ID NOs:
347, 119, 356, 341, 359, and 362, respectively;
(lxi) SEQ ID NOs:
346, 119, 356, 341, 359, and 362, respectively;
(lxii) SEQ ID NOs:
95, 119, 356, 341, 187, and 362, respectively;
(lxiii) SEQ ID NOs:
95, 352, 356, 341, 187, and 362, respectively;
(lxiv) SEQ ID NOs:
95, 350, 356, 341, 359, and 362, respectively;
(lxv) SEQ ID NOs:
95, 353, 356, 341, 359, and 362, respectively;
(lxvi) SEQ ID NOs:
95, 351, 356, 341, 359, and 362, respectively;
(lxvii) SEQ ID NOs:
95, 350, 356, 341, 359, and 362, respectively;
(lxviii) SEQ ID NOs:
346, 354, 356, 341, 359, and 363, respectively;
(lxix) SEQ ID NOs:
346, 348, 356, 357, 359, and 362, respectively;
(lxx) SEQ ID NOs:
346, 354, 356, 358, 187, and 362, respectively;
(lxxi) SEQ ID NOs:
95, 348, 151, 181, 187, and 208, respectively;
(lxxii) SEQ ID NOs:
90, 364, 373, 376, 388, and 231, respectively;
(lxxiii) SEQ ID NOs:
90, 364, 155, 377, 203, and 231, respectively;
(lxxiv) SEQ ID NOs:
90, 364, 374, 378, 203, and 231, respectively;
(lxxv) SEQ ID NOs:
90, 365, 155, 376, 203, and 392, respectively;
(lxxvi) SEQ ID NOs:
90, 364, 155, 376, 389, and 231, respectively;
(lxxvii) SEQ ID NOs:
90, 364, 155, 379, 203, and 231, respectively;
(lxxviii) SEQ ID NOs:
90, 366, 155, 380, 203, and 231, respectively;
(lxxix) SEQ ID NOs:
90, 364, 373, 381, 203, and 231, respectively;
(lxxx) SEQ ID NOs:
90, 367, 155, 382, 203, and 231, respectively;
(lxxxi) SEQ ID NOs:
90, 368, 155, 383, 203, and 231, respectively;
(lxxxii) SEQ ID NOs:
90, 364, 374, 384, 203, and 231, respectively;
(lxxxiii) SEQ ID NOs:
90, 368, 155, 376, 203, and 293, respectively;
(lxxxiv) SEQ ID NOs:
90, 364, 155, 378, 203, and 231, respectively;
(lxxxv) SEQ ID NOs:
90, 368, 155, 376, 203, and 231, respectively;
(lxxxvi) SEQ ID NOs:
90, 369, 155, 378, 203, and 394, respectively;
(lxxxvii) SEQ ID NOs:
90, 364, 155, 378, 203, and 231, respectively;
(lxxxviii) SEQ ID NOs:
90, 370, 155, 378, 203, and 394, respectively;
(lxxxix) SEQ ID NOs:
90, 371, 155, 378, 203, and 394, respectively;
(xc) SEQ ID NOs:
90, 368, 155, 385, 203, and 394, respectively;
(xci) SEQ ID NOs:
90, 368, 155, 378, 203, and 395, respectively;
(xcii) SEQ ID NOs:
90, 368, 155, 378, 390, and 394, respectively;
(xciii) SEQ ID NOs:
90, 372, 155, 378, 391, and 394, respectively;
(xciv) SEQ ID NOs:
90, 368, 375, 386, 203, and 394, respectively;
or
(xcv) SEQ ID NOs:
90, 368, 155, 387, 203, and 394, respectively.

186 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/118,921Filed 11 Dec 2020

Priority

13 Dec 2019

Published

26 Aug 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 16/40
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against enzymes
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
A61P 35/00
Antineoplastic agents
C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152

Family

Application62/947,855Us provisional application · filed 13 Dec 2019

Application63/016,821Us provisional application · filed 28 Apr 2020

Application63/121,773Us provisional application · filed 4 Dec 2020

US 11,897,968 B2Related patent

US 2021/0261685 A1This patent

From the US filing history. Foreign family members aren’t listed.

Anti-mertk antibodies and methods of use thereof

Life of this patent

Abstract

Claims36

Anti-mertk antibodies and methods of use thereof

Life of this patent

Abstract

Claims36